Tipping Point for Verified Clinical Trials: When Is Enough, Enough with Duplicate and Professional Subjects in Clinical Trials?
Clinical research has long tolerated a quiet but persistent risk: duplicate subjects in clinical trials, professional research subjects, and dual enrollment in clinical trials.For years, these issues were viewed as operational nuisances—manageable, unfortunate, but expected. Sponsors adjusted. Sites absorbed the burden. CROs implemented workarounds. But at what point does “manageable” become materially dangerous? At what …